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Abstract
Background: XIAP-associated factor 1 (XAF1) is a putative tumor suppressor that exerts its
proapoptotic effects through both caspase-dependent and – independent means. Loss of XAF1
expression through promoter methylation has been implicated in the process of tumorigenesis in
a variety of cancers. In this report, we investigated the role of basal xaf1 promoter methylation in
xaf1 expression and assessed the responsiveness of cancer cell lines to XAF1 induction by IFN-β.
Methods: We used the conventional bisulfite DNA modification and sequencing method to
determine the methylation status in the CpG sites of xaf1 promoter in glioblastoma (SF539, SF295),
neuroblastoma (SK-N-AS) and cervical carcinoma (HeLa) cells. We analysed the status and
incidence of basal xaf1 promoter methylation in xaf1 expression in non-treated cells as well as
under a short or long exposure to IFN-β. Stable XAF1 glioblastoma knock-down cell lines were
established to characterize the direct implication of XAF1 in IFN-β-mediated sensitization to
TRAIL-induced cell death.
Results: We found a strong variability in xaf1 promoter methylation profile and responsiveness to
IFN-β across the four cancer cell lines studied. At the basal level, aberrant promoter methylation
was linked to xaf1 gene silencing. After a short exposure, the IFN-β-mediated reactivation of xaf1
gene expression was related to the degree of basal promoter methylation. However, in spite of
continued promoter hypermethylation, we find that IFN-β induced a transient xaf1 expression, that
in turn, was followed by promoter demethylation upon a prolonged exposure. Importantly, we
demonstrated for the first time that IFN-β-mediated reactivation of endogenous XAF1 plays a
critical role in TRAIL-induced cell death since XAF1 knock-down cell lines completely lost their
IFN-β-mediated TRAIL sensitivity.
Conclusion: Together, these results suggest that promoter demethylation is not the sole factor
determining  xaf1  gene induction under IFN-β treatment. Furthermore, our study provides
evidence that XAF1 is a crucial interferon-stimulated gene (ISG) mediator of IFN-induced
sensitization to TRAIL in cancer.
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Background
Cell life and death decisions rely on a delicate balance
between pro- and anti-apoptotic factors. A disruption of
this balance can result in a variety of pathologies includ-
ing cancer, autoimmune and neurodegenerative diseases.
In cancer cells, anti-apoptotic factors such as the Inhibi-
tors of Apoptosis (IAPs) render cells resistant to apoptosis,
primarily through their inhibition of core death execu-
tioners, the caspases, or through the neutralization of
antagonists such as Smac/DIABLO and Omi/HtrA2 [1]. In
particular, Baculovirus IAP Repeat domains (BIRs) present
in XIAP can interact directly and inhibit initiator and/or
effector caspases. In addition, the RING finger domain
present in some IAPs such as XIAP and cIAP-1 acts as an
E3 ubiquitin ligase, targeting the IAP-caspase complex for
degradation via the proteasome [2]. Thus, IAP function is
central to the modulation of the apoptotic cascade.
To counter the effects of the IAPs, several antagonists such
as XIAP-Associated Factor-1 (XAF1), Smac/DIABLO and
Omi/HtrA2 have been identified that play essential roles
in apoptosis [3]. XAF1 has been independently identified
in several screens as a key mediator of apoptosis [4-6] and
is shown to dramatically sensitize cancer cells to apoptotic
triggers such as TNF-related apoptosis-inducing ligand
(TRAIL) and etoposide treatments [4,7]. This sensitization
is in part achieved through XAF1 inhibition of XIAP anti-
caspase activity. In addition, XAF1 also appears to
enhance the apoptotic effects of TNF-α independently of
its interaction with XIAP [8]. Furthermore, in urogenital
cancers, XAF1 was recently shown to quicken the apopto-
sis response through its enhancement of p53 protein sta-
bility [6]. These recent findings identify XAF1 as a
candidate tumor suppressor at the junction of several
major pathways leading to apoptosis.
The loss of XAF1 is associated with malignant tumor pro-
gression in a variety of cancers. XAF1 levels are drastically
decreased in a significant number of cancer cell lines [5,9],
as well as in a collection of gastric cancers [10], melanoma
specimens [5] and urogenital cancers [6]. Loss of XAF1 is
due, at least in part, to epigenetic alterations such as DNA
methylation at several CpG sites within the promoter
region [6,10]. In gastric cancers, the relative decrease in
xaf1 transcript level correlates with the stage and grade of
the tumor, suggesting that loss of XAF1 contributes to the
process of tumorigenesis [10]. It is therefore predicted that
methods that enhance XAF1 levels could increase apop-
totic susceptibility and provide an additional strategy for
cancer therapy.
In this context, the discovery of xaf1 as an Interferon Stim-
ulated Gene (ISG) provides evidence for the feasibility of
such a therapeutic strategy. The induction of XAF1 by IFN-
β in human melanoma cell lines results in enhanced sus-
ceptibility to TRAIL-induced apoptosis [7]. Expression of
a truncated XAF1 protein lacking part of a zinc-finger
domain abrogates IFN-dependent sensitization to TRAIL,
suggesting that XAF1 plays an essential role in IFN-medi-
ated apoptosis. A potential pitfall of the use of IFN to
induce xaf1 expression is the frequent hypermethylation
of the xaf1 promoter observed in many cancer cell lines
[6,10]. Promoter hypermethylation can lead to transcrip-
tional gene silencing through the assembly of condensed
chromatin domains or through simple inhibition of tran-
scription factor binding [11]. DNA methylation and the
subsequent silencing of several IFN pathway components
including RNAseL and RNA-activated protein kinase
(PKR) has been identified as a major mechanism associ-
ated with carcinogenesis [12,13]. The reversal of the DNA
methylation status, through treatment with the methyl-
transferase inhibitor 5-aza-2'-deoxycytidine (5-AZA-dC)
can restore cell susceptibility to IFN [13,14]. Although in
the large majority of cases there is a strong correlation
between promoter methylation and resistance to induc-
tion by IFN, exceptions exist. In neuroblastoma cells,
treatment with IFN-γ can induce methylation-silenced
caspase-8 expression without affecting the methylation
status within the promoter region [15]. As a plausible
explanation, an alternative IFN-inducible promoter ele-
ment has been found upstream of the first exon of caspase-
8 gene and has been shown to be responsive to IFN-γ,
independently of the methylation status [15,16].
In this report, we investigate the effect of IFN-β on the
methylation status of xaf1 promoter and on the expres-
sion of xaf1 in SF539 and SF295 glioblastoma, SK-N-AS
neuroblastoma and HeLa cervical carcinoma. In cancer
cells, we find a strong correlation between methylation
status of the xaf1 promoter and baseline gene expression
at the transcript level. HeLa and SK-N-AS cell lines show
the highest basal promoter hypermethylation among the
four cancer cell lines studied compared to control cells,
and are used as cellular models for studying the respon-
siveness of IFN-β-mediated XAF1 induction. In spite of
basal promoter hypermethylation, IFN-β could induce
xaf1  expression in HeLa and SK-N-AS. Futhermore, we
demonstrate that IFN-β induced a transient increase in the
xaf1 transcript and protein levels apparent at 48 hours
post-treatment. However, we do not find a tight link
between IFN-β-mediated  xaf1  gene induction and
decrease in average methylation within xaf1  promoter
region in HeLa and SK-N-AS cells occurring at later time
points. These results suggest that xaf1 expression would be
positively regulated by additional mechanisms other than
promoter demethylation. To further understand the
importance of xaf1 gene induction in IFN-β-sensitization
to TRAIL-mediated cell death, we established stable gliob-
lastoma SF539 cell lines carrying specific xaf1 shRNA. We
find that xaf1 knockout stable SF539 clones are unrespon-BMC Cancer 2007, 7:52 http://www.biomedcentral.com/1471-2407/7/52
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sive to IFN-β-mediated XAF1 induction, rendering these
stable cell lines resistant to sensitization by IFN-β to
TRAIL-mediated cell death. Our study clearly demon-
strates that xaf1 is a critical ISG implicated in IFN-β-medi-
ated sensitization to TRAIL-induced cell death.
Methods
Cell culture and transfection
Glioblastoma (SF539 and SF295) and neuroblastoma
(SK-N-AS) cell lines were maintained on Dulbecco's Mod-
ified Eagle Medium (DMEM), 10% foetal bovine serum
(FBS), supplemented with 4 mM glutamine and 0.1 mM
non-essential amino-acids. Cervical carcinoma (HeLa)
cells were maintained in Minimal Essential Medium
(MEM), 10% FBS supplemented with 2 mM glutamine
and 0.1 mM non-essential amino acids. For transfection,
cells were grown to 70%–80% confluency in 6-well plates
and transfected with linearized plasmid DNA using Lipo-
fectamine 2000 (Invitrogen, Burlington ON, Canada)
according to the manufacturer's recommendations. Stable
clones were selected in DMEM supplemented with 600
μg/mL G418 (Invitrogen).
When required, IFN-β (R&D Systems, Minneapolis, MN,
USA) was added at a concentration of 500 U/mL and 5-
aza-2'-deoxycytidine (Sigma-Aldrich) at the doses indi-
cated.
Xaf1 short hairpin RNA (shRNA) plasmid construction and 
screening
The design and construction of the shRNA clones against
xaf1  was performed according to the shagging-PCR
method described previously [17]. PCR amplification
reactions were performed on U6 promoter template using
a forward primer (5'-AGGAGATCTGCGCAGGCAAAACG-
CACCAC-3') and a variety of 96 nucleotide-long shRNA
xaf1 primers based on a similar approach described previ-
ously for shRNA XIAP [18]. PCR products were cloned
into a TOPO-TA vector (Invitrogen) and were screened for
activity by transient transfection into 293T cells followed
by xaf1 transcript quantification by quantitative RT-PCR.
One of the constructs that caused a significant decrease in
xaf1 transcript levels was selected for stable transfection
into glioblastoma SF539 cells. The construct targets exon-
2 that is shared among the three major splice isoforms of
xaf1 (5'-CCATGGAGGAGCACTGCAAGCTTGAGCAC-3').
The shRNA was sub-cloned into a pCDNA3 vector devoid
of its CMV promoter [18] and transfected into SF539 cells
as described above.
Quantitative RT-PCR
Quantitative RT-PCR using xaf1-specific primers and the
TaqMan method [19] was performed as described previ-
ously [9]. Briefly, total RNA was extracted from 1 × 107
cells using the RNeasy kit (Qiagen, Mississauga ON, Can-
ada). 100 ng aliquots were assayed by reverse-transcrip-
tion followed by PCR (TaqMan EZ-RT PCR kit, Applied
Biosystems, Foster City CA, USA) with xaf1-specific
primer/probe combinations [9]. GAPDH primer and
probes were used as a control. All assays were performed
at least in triplicate.
Western blot analysis
Cells were grown in 6-well plates at a density of ~7 × 105
cells per well. Cells were either treated or not with IFN-β
(500 U/mL) for 24 hours or more, harvested by scraping,
washed twice in PBS (pH 7.2) and lysed with boiling lysis
buffer (1% SDS, 1 mM ortho-vanadate, 10 mM tris pH
7.4). Protein concentration was determined with the RC
DC Bradford assay (BioRad, Montreal QC, Canada). 20 μg
to 30 μg of total protein in SDS sample buffer was
resolved by SDS-PAGE (10% or 12.5%) and transferred to
PVDF membrane using a semi-dry transfer system
(Hoepher SemiPhor). Membranes were blocked over-
night in PBS (0.1% Tween, 5% skim milk) and were incu-
bated with primary antibody (PBS, 2% skim milk) for 12
to 16 hours at 4°C. The membrane was incubated with
secondary antibody (PBS, 2% skim milk) for two hours
and the signal was revealed by enhanced chemilumines-
cence (ECL) or ECL-Plus kits (Amersham Biosciences,
Baie d'Urfe, QC, Canada). Mouse monoclonal anti-XAF1
and rabbit polyclonal anti-XIAP antibodies were gener-
ated against their respective full-length GST-tagged con-
struct following standard techniques. Antibodies against
β-actin and GAPDH were obtained from Sigma and
Advanced Immunochemical, respectively.
Bisulphite DNA sequencing
Cells were grown to 80% confluency in 10 cm plates and
harvested by scraping. Genomic DNA was extracted using
the DNeasy kit (Qiagen). Approximately 1 μg of DNA was
modified with sodium bisulphite as outlined previously
[20]. Modified DNA was used as a template in PCR reac-
tions with primers MS2 and MS3 [10]. PCR products were
cloned into TOPO-TA vector and transformed into E. coli
XL-10 gold cells (Stratagene) and 10 positive clones were
randomly selected for sequencing. Methylation status was
assessed at eight CpG sites situated within a 250 bp region
upstream of the translational start site, whose methylation
status was previously shown to correlate with xaf1 gene
silencing [10]. As a control, DNA was extracted from buffy
coat preparations of blood samples donated by two
healthy volunteers. Control DNA was processed as
described above.
Cell viability assay
Cells were seeded in 96 well plates at 1 × 105 cells per well
(100 μl of medium) and were allowed to adhere for at
least 8 hours. Growth medium was replaced with medium
containing TRAIL at concentrations ranging from 0 to 100BMC Cancer 2007, 7:52 http://www.biomedcentral.com/1471-2407/7/52
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ng/mL and cell viability was assessed 16 to 20 hours later
by the WST-1 assay (Roche Diagnostics, Laval QC Can-
ada).
Results
Relationship between basal profile of xaf1 promoter 
methylation and IFN-β-mediated induction of xaf1 
expression
Four cancer cell lines, SF295, SF539, SK-N-AS and HeLa
were selected to investigate the effect of xaf1 promoter
methylation on IFN-β mediated xaf1 induction. Of these,
glioblastoma SF295 cells have previously been shown to
carry little or no detectable XAF1 protein [4]. In contrast,
the SF539 cell line expresses substantial amounts of XAF1
protein, compared to other cancer cell lines examined [4].
In order to assess the degree of xaf1 promoter methylation
within these cell lines, a bisulphite DNA modification and
sequencing was performed. The methylation status of 8
CpG sites situated within a 250 bp region immediately
upstream of the translational start and corresponding to
part of the xaf1 promoter was PCR amplified and 10 PCR
clones were isolated and sequenced (Figure 1A and 1B).
The methylation status was compared to control total
blood DNA obtained from healthy volunteers. Cancer cell
lines tested vary extensively in their degree of methylation
(Figure 1B). HeLa (average methylation at all sites 37.5%)
and SK-N-AS (77.5%) cells display significantly more
methylated CpG sites than control samples (9.3%), SF295
(0%) and SF539 (1.3%) (Figure 1C). The degree of pro-
moter methylation is inversely correlated with xaf1 tran-
script levels measured by quantitative RT-PCR (Figure
1D). Cell lines SF539 and SF295 that display low pro-
moter methylation have comparatively more xaf1 tran-
script than HeLa and SK-N-AS cell lines.
To assess the effect of IFN-β on xaf1 gene expression in the
context of basal xaf1  promoter methylation, cells were
treated with 500 U/mL IFN-β for 24 hours and xaf1 tran-
script levels were measured by quantitative RT-PCR (Fig-
ure 1D). A strong inverse correlation exists between basal
xaf1 promoter methylation and transcription induction
by IFN-β. Cell lines displaying high levels of basal meth-
ylation (e.g. SK-N-AS and HeLa) show minimal xaf1
induction, whereas cell lines with no or little methylation
display enhanced levels of xaf1 transcript (e.g. SF295 and
SF539) in response to IFN-β. IFN-β treatment also causes
a significant increase in XAF1 protein level in cell lines dis-
playing low levels of basal promoter methylation (Figure
1E). XAF1 protein induction is not detectable in cell lines
with very high levels of promoter methylation (data not
shown).
To assess the effect of IFN-β on XAF1 protein expression
under demethylating conditions, we have compared the
effects of the DNA methylation inhibitor 5-AZA-dC and
IFN-β treatment alone and in combination. Treatment
with 5-AZA-dC alone up-regulated the expression of XAF1
in HeLa cells (hypermethylated xaf1 promoter at baseline)
but had no effect in SF295 (hypomethylated xaf1 pro-
moter at baseline) used as a control. The combination of
5-AZA-dC and IFN-β synergistically induced XAF1 expres-
sion in HeLa cells. However, no such effect was detected
in cell lines lacking xaf1 promoter methylation (SF295)
(Figure 1F). Treatment with IFN-β induced XAF1 expres-
sion regardless of the promoter methylation status of the
cells suggesting a more complex mechanism of xaf1 tran-
scriptional regulation.
Methylation dynamics of xaf1 promoter in cancer cell lines 
after prolonged IFN-β treatment
The observation that cell lines heavily methylated within
the xaf1 promoter still respond to IFN-β treatment (i.e.
72- and 266-fold xaf1 transcript induction in SK-N-AS and
HeLa cells, respectively, Figure 1C) suggested that tran-
scriptional silencing associated with xaf1 promoter meth-
ylation may be reversible. To address this possibility, we
surveyed xaf1 promoter methylation status in HeLa and
SK-N-AS cells exposed of 500 U/mL IFN-β for up to five
days, followed by a seven-day recovery in medium with-
out IFN-β. A continuous five day treatment with IFN-β
caused a significant demethylation of most previously
methylated CpG sites that was confirmed by bisulfite
DNA modification and sequencing analysis (Figure 2A).
Indeed, IFN-β caused a net 76% and 44% reduction in
promoter methylation in HeLa and SK-N-AS cells, respec-
tively (Figures 2A and 2B). After 7 days without IFN-β, the
level of methylation remained unchanged, indicating that
the demethylated status of xaf1 promoter was stable.
Next, we analyzed the expression levels of xaf1 transcript
(Figures 3A and 3B) and protein (Figure 3C) following the
5-day IFN-β treatment and 7-day recovery. Intriguingly, in
the presence of IFN-β, there is no discernible correlation
between promoter demethylation and transcript increase
(Figures 2 and 3). Xaf1 transcript and protein levels are
correlated to each other, reaching a peak at 48 hours and
declining subsequently in both cell lines. Moreover, after
IFN-β removal and despite sustained promoter demethyl-
ation,  xaf1  transcript and protein levels continue to
decrease. Thus, although IFN-β treatment resulted in a
sustained loss of DNA methylation within the promoter
region of xaf1, this treatment was not sufficient in main-
taining increased xaf1 transcript or protein levels in the
long term.
Endogenous XAF1 is critical for IFN-β-mediated TRAIL-
dependent apoptosis
To place xaf1 in a therapeutic context, we evaluated the
role of xaf1 expression in susceptibility to TRAIL-induced
apoptosis in glioblastoma cells SF539. A previous studyBMC Cancer 2007, 7:52 http://www.biomedcentral.com/1471-2407/7/52
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Effect of IFN-β treatment on xaf1 transcript and protein levels in selected cell lines Figure 1
Effect of IFN-β treatment on xaf1 transcript and protein levels in selected cell lines. (A) Schematic representation 
of the 8 CpG sites of the 5' upstream region of the xaf1 gene. (B) Methylation status of xaf1 promoter region in selected cell 
lines was determined based on analysis of 8 CpG sites by methylation-sensitive PCR. Genomic DNA was treated with sodium 
bisulphite. PCR products with MS2 (P1) and MS3 (P2) primers were cloned into the TopoTA vector and sequenced. Ten 
cloned PCR products were sequenced for each cell line. Black, dark gray/light gray and open circles represent complete meth-
ylation, partial methylation and unmethylation at each CpG site, respectively. Controls are total blood DNA from healthy vol-
unteers. (C) Graph representing the percentage of average methylation at all sites in selected cell lines. (D) xaf1 transcript 
levels were assessed by quantitative RT-PCR on total RNA and indexed to GAPDH transcript levels in non-treated cells (NT) 
and cells exposed to 500 U/mL of IFN-β for 24 hours. The protein level of endogenous (E) or induced (F) XAF1 was deter-
mined by western blot analysis, 30 μg of total protein extract were resolved by 12% SDS-PAGE and XAF1 was detected using 
an anti-XAF1 mouse monoclonal antibody. Membranes were stripped and re-probed with anti-β-actin antibody as a loading 
control. (F) Cells were left untreated (NT), exposed to 500 U/mL of IFN-β (IFN) for 24 hours or treated with 5-AZA-dC at 
the indicated concentration, followed 24 hours later by IFN-β for 24 hours. The blot in (E) was intentionally overexposed to 
increase the weak signal of XAF1 in SF295 cells (F).
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Effect of IFN-β on methylation dynamics of xaf1 promoter Figure 2
Effect of IFN-β on methylation dynamics of xaf1 promoter. Cells were exposed to 500 U/mL of IFN-β in culture 
medium for 0 hour, 24 hours, 48 hours or 5 days. (A) The methylation status of xaf1 promoter region in HeLa and SK-N-AS 
cells was determined based on the analysis of 8 CpG sites, by methylation-sensitive PCR as described previously in Figure 1. (B) 
HeLa and (C) SK-N-AS cells were treated for 5 days, and then were subsequently sub-cultured on medium lacking IFN-β for 7 
days. Genomic DNA was harvested and subjected to sodium bisulphite treatment and PCR using primers MS2 and MS3. 
Results represent average methylation for 10 independent clones at 8 representative CpG sites for each cell line. After 5 days 
of continuous exposure to IFN-β there is a significant overall drop (p < 0.05) in methylation within the xaf1 promoter region.
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Effect of IFN-β exposure on xaf1 expression at the transcript and protein levels Figure 3
Effect of IFN-β exposure on xaf1 expression at the transcript and protein levels. HeLa (A) and SK-N-AS (B) cells 
treated with 500 U/mL IFN-β for 0 hour, 24 hours, 48 hours or 5 days, or after a 7-day IFN-β free period were harvested, total 
RNA was extracted and subjected to quantitative RT-PCR and indexed to GAPDH transcript levels. (C) 30 μg of total protein 
extract were resolved by 12% SDS-PAGE and XAF1 was detected using an anti-XAF1 mouse monoclonal antibody. Loading 
was checked by using an anti-β-actin monoclonal antibody.
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has shown that overexpression of xaf1 promotes TRAIL-
induced apoptosis in melanoma cells [7]. Here, glioblast-
oma cells SF539 that display relatively high levels of xaf1
transcript, XAF1 protein and very low levels of promoter
methylation were assessed for their susceptibility to
TRAIL-induced apoptosis before and after shRNA-medi-
ated xaf1 silencing. Due to the poor efficiency of transfec-
tion (20 to 30%) of the SF539 cells, stable clones (SFX1,
SFX3, SFX4) expressing a shRNA construct directed
against xaf1 were generated. These clones display a com-
plete downregulation of endogenous XAF1 protein levels
and abrogate XAF1 induction even after 24 hours of IFN-
β treatment (Figure 4). Interestingly, treatment with IFN-
β also causes a significant decrease in XIAP protein levels
that appears to be at least in part dependent on the induc-
tion of XAF1, since this decrease is less marked in shRNA
stable cell lines lacking XAF1.
Three of the stable xaf1 shRNA clones as well as the paren-
tal SF539 cell line were subjected to various concentra-
tions of TRAIL with or without prior IFN-β treatment. As
expected, IFN-β sensitized SF539 cells to TRAIL-induced
cell death throughout the range of concentrations used in
this experiment (Figure 5). In contrast, all three stable cell
lines display a loss of IFN-β-mediated sensitivity to TRAIL,
even though they differ in their TRAIL resistance in the
absence of IFN-β. Together, these results demonstrate that
the induction of endogenous XAF1 by IFN-β plays a criti-
cal role in sensitizing cancer cells to TRAIL-induced cell
death.
Discussion
In this study we have explored the relationship of XAF1
expression to gene silencing, promoter methylation and
gene induction by IFN-β. Previous studies had indicated
that loss of xaf1 expression, due at least in part to pro-
moter methylation, is associated with increased tumor
severity in gastric [10] and urogenital cancers [6]. In addi-
tion, XAF1 was shown to play a key role in the mechanism
of IFN-β-associated sensitization to apoptotic cell death
induced by TRAIL [7]. More recently, XAF1 was demon-
strated to be critical in overcoming resistance to apoptosis
induction by IFN-β in renal carcinoma and melanoma
cells [21].
First, we validated the relationship between xaf1 silencing
and promoter hypermethylation across four cancer cell
lines HeLa, SK-N-AS, SF539 and SF295, that was to date,
unexplored in this context. Then, we demonstrated that
reverse methylation is not an absolute prerequisite for
IFN-β-mediated XAF1 induction, since we showed a tran-
sient induction of XAF1 at both transcript and protein lev-
els in spite of aberrant methylation, more particularly in
HeLa cells. Finally, our results strengthen the importance
of XAF1 expression in IFN-β-mediated sensitization to
TRAIL-induced cell death in cancer cells.
Our current analysis of the methylation status of the xaf1
promoter is limited to the examination of 8 CpG sites
within the proximal promoter region. These CpG sites
have been previously validated to be more tightly associ-
ated with xaf1  expression compared with others distal
CpG sites investigated [10]. In addition, very recently, 2 of
the 8 CpGs at -2nd, -1st positions (with respect of the tran-
scriptional start site) were found to be more important in
xaf1  transcriptional regulation [22]. However, further
studies combining site-directed mutagenesis with methyl-
ation techniques will be necessary to ascertain the rele-
vance of these sites in order to demonstrate if some of
them are functionally more important than others.
Our results indicate that mechanisms, in addition to DNA
methylation, are responsible for the control of XAF1
expression in cancer cells. Consistent with the pleitropic
nature of IFN-β, multiple signalling pathways can be
expected to be activated upon IFN-β challenge. For exam-
ple, a large body of evidence has shown that the interac-
tion of IFN-β with its receptor complex induces the
transcription of ISGs through a signalling pathway involv-
ing the activation of the Janus kinase (JAK) family that in
turn, phosphorylate substrate proteins called STATs (sig-
nal transducers and activators of transcription) [23]. In
addition, the family of transcription factors known as
interferon regulatory factors (IRFs) contribute to the
numerous biological functions of IFN-α and IFN-β, which
then modulate different sets of genes including IFN-α/β
and many ISGs genes [24,25]. Interestingly, after treat-
ment of human hepatoma cells with a combination of
IFN-α and IFN-γ, transcriptional induction of selective
ISGs (including xaf1) was found to be dependent upon
IRF-1 [26].
In accordance with previous reports, we find a strong
inverse correlation between xaf1 promoter methylation
and baseline transcript in four cancer cell lines tested. In
spite of the high level of promoter methylation in HeLa
and SK-N-AS cell lines, a significant increase in xaf1 tran-
script and protein levels was detected following IFN-β
treatment. Although the responsiveness to IFN-β-medi-
ated XAF1 induction is generaly more effective in cells
associated with low basal xaf1 promoter methylation, our
results indicate that reverse methylation is not the sole fac-
tor modulating XAF1 expression. In this regard, we dem-
onstrate that IFN-β has the ability to overcome the
epigenetic modification of hypermethylation. Consistent
with this result, IFN was previously found to mediate the
induction of caspase-8 in neuroblastomas, without affect-
ing promoter methylation [15,16]. Nevertheless, pro-
longed exposure to IFN-β leads to significant and stableBMC Cancer 2007, 7:52 http://www.biomedcentral.com/1471-2407/7/52
Page 9 of 12
(page number not for citation purposes)
demethylation of the xaf1  promoter, but long-term
expression of the xaf1 transcript and protein remain unaf-
fected by the treatment. We have attempted to provide
explanation as to the mechanisms that governs xaf1
demethylation under IFN-β treatment, with respect to the
role of DNMTs known in maintaining genes like xaf1
silenced [21,27]. We have demonstrated a synergistic
effect of treatments combining the inhibitor of DNMTs, 5-
AZA-dC, and IFN-β on XAF1 re-expression in cells with
hypermethylated xaf1 promoter. This suggests that IFN-β
may overcome DNMT activity to a certain extent, a finding
that is consistent with a previous study showing that selec-
tive depletion of DNMT1 leads to demethylation and sub-
sequent reactivation of xaf1 expression. Moreover, in this
context, IFN-β-induced apoptosis was found to be
dependent on xaf1 expression [21]. Xaf1 promoter meth-
ylation represents an initial mechanism of apoptosis
resistance displayed by cancer cells. In this regard, it
would be interesting to examine the correlation between
DNA methyltransferases expression and xaf1  promoter
methylation status in various cancer cell lines to evaluate
their response to IFN-β-induced apoptosis.
These findings stress the importance of factors independ-
ent from DNA methylation that directly or indirectly con-
trol xaf1 expression. Very recently, studies have reported
new transcriptional regulatory elements within the proxi-
mal 5' region of xaf1 promoter. Interestingly, under spe-
cific stress pressure, the heat-shock transcription factor 1
(HSF1) was demonstrated to function as a negative regu-
lator of xaf1 expression in various gastroinstestinal cancer
tissues and cell lines [28]. However, the potential influ-
ence of DNA methylation on HSF1 binding-mediated
suppression of XAF1 transcription has not been studied.
Stable XAF1 knockout cell lines are resistant to IFN-β-mediated XAF1 induction Figure 4
Stable XAF1 knockout cell lines are resistant to IFN-β-mediated XAF1 induction. The parental SF539 cell line and 
3 stable xaf1 shRNA clones (SFX1, SFX3, SFX4) were exposed to 0 or 500 U/mL IFN-β for 24 hours. Total protein extracts 
were resolved by 12% SDS-PAGE and sequentially probed with XAF1, XIAP and GAPDH antibodies.
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XAF1 is essential for IFN-β-mediated TRAIL-dependent apoptosis Figure 5
XAF1 is essential for IFN-β-mediated TRAIL-dependent apoptosis. SF539 (A) and 3 stable xaf1 shRNA clones (B-D) 
were treated with 0 or 500 U/mL of IFN-β for 24 hours prior to exposure to TRAIL for 14 hours. Cell viability was measured 
with the WST-1 assay as described in the methods and materials section. All assays were performed in triplicate and experi-
ments were repeated at least three times.
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Conversely, XAF1 was found to be modulated positively
(independently of DNA methylation) by all-trans retinoic
acid (ATRA) and IFN through an IFN regulatory factor 1
binding element (IRF-E) that mediates transcription regu-
lation and participates in ATRA-induced induced cell-
growth suppression [29]. However a significant contribu-
tion of HSF1 or IRF-1 in IFN-β-mediated transient XAF1
expression observed in our study remains to be con-
firmed. On the other hand, IFN-β induces ISGs of which
xaf1 is a member, through a JAK kinase cascade which in
turn activates STAT factors [23,30]. Therefore, modifica-
tions in the activity of any of the members of the IFN-β
cascade can be potentially responsible for modifications
in xaf1 transcription that are independent of xaf1 pro-
moter methylation.
We have demonstrated that endogenous XAF1 expression
is crucial for the IFN-β-associated sensitization to TRAIL.
The loss of XAF1 in three different shRNA stable glioblas-
toma cell lines completely abolished the sensitization
effect of IFN-β observed in the parental SF539. The lack of
XAF1 induction following IFN-β treatment in these stable
cell lines demonstrates the efficacy of the shRNAs in sup-
pressing XAF1 expression even in the presence of a proven
inducer of the gene. Importantly, these findings allowed
us to examine the relationship between endogenous
XAF1, IFN-β and TRAIL-mediated apoptosis. Significantly,
a previous report has demonstrated the critical role of
XAF1 in overcoming resistance to IFN-β-induced apopto-
sis in the absence of DNMT1 expression, a result that sup-
ports our current findings [21].
Among the multitude of genes that are modulated by IFN
[31,32] and can potentially enhance cell sensitivity to
TRAIL-induced apoptosis, we show that xaf1  alone is
important and essential in mediating susceptibility to
TRAIL-induced apoptosis in cancer cells. Functional
knockdown of xaf1 through shRNA is sufficient to elimi-
nate the IFN-β-mediated sensitization to TRAIL in gliob-
lastoma cells. Although TRAIL is a potent apoptotic trigger
in many cancer cells, resistance to TRAIL, either intrinsic
or acquired, currently represents a substantial limitation
to therapy [33]. IFN treatment has been shown to over-
come TRAIL resistance [34], however, resistance to the
dual IFN/TRAIL therapy has also been observed [35]. In
this context, the centrality of XAF1 in IFN-regulated apop-
tosis might be the key in reversing TRAIL-resistance.
Conclusion
In conclusion, we demonstrate that, in spite of aberrant
hypermethylation of the xaf1  gene, IFN-β was able to
induce xaf1 expression. Furthermore, although promoter
methylation is a good predictor to basal XAF1 expression,
demethylation does not necessarily lead to sustained
XAF1 expression. However, it is clear that XAF1 is an
important mediator in sensitizing IFN-treated cells to
TRAIL-induced killing. These results suggest that the
incorporation of xaf1 in combination regimens might be
of particular value in TRAIL-based anti-cancer strategies.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
OCM carried out the experiments and wrote the first draft.
HHC did experiments and helped to draft the manuscript.
SP provided technical expertise, helped to draft, and final-
ized the manuscript. SLH provided technical help at the
DNA methylation analysis. EL aided in the generation of
XAF1 shRNA vectors. PL and RGK both conceived and
coordinated the study. All authors read and approved the
final manuscript.
Acknowledgements
We would like to thank Dr. D. McManus for providing the U6 RNA PolIII 
promoter and all the staff of ARC and the CHEO Research Institute for 
their helpful technical assistance and discussions. This work was supported 
by grants from the Canadian Institutes of Health Research (CIHR) and the 
Howard Hughes Medical Institute (HHMI). HHC is a recipient of a post-
doctoral Fellowship from the CIHR. SP is a recipient of a post-doctoral Fel-
lowship from the Natural Sciences and Engineering of Research Council of 
Canada (NSERC). RGK is a HHMI International Research Scholar and a Fel-
low of the Royal Society of Canada.
References
1. Wright CW, Duckett CS: Reawakening the cellular death pro-
gram in neoplasia through the therapeutic blockade of IAP
function.  J Clin Invest 2005, 115:2673-2678.
2. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD: Ubiquitin pro-
tein ligase activity of IAPs and their degradation in proteas-
omes in response to apoptotic stimuli.  Science 2000,
288:874-877.
3. Liston P, Fong WG, Korneluk RG: The inhibitors of apoptosis:
there is more to life than Bcl2.  Oncogene 2003, 22:8568-8580.
4. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K,
Craig CG, McBurney MW, Korneluk RG: Identification of XAF1
as an antagonist of XIAP anti-Caspase activity.  Nat Cell Biol
2001, 3:128-133.
5. Ng KC, Campos EI, Martinka M, Li G: XAF1 expression is signifi-
cantly reduced in human melanoma.  J Invest Dermatol 2004,
123:1127-1134.
6. Lee MG, Huh JS, Chung SK, Lee JH, Byun DS, Ryu BK, Kang MJ, Chae
KS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG: Promoter CpG
hypermethylation and downregulation of XAF1 expression
in human urogenital malignancies: implication for attenu-
ated p53 response to apoptotic stresses.  Oncogene 2006,
25:5807-5822.
7. Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S,
Borden EC: Identification of X-linked inhibitor of apoptosis-
associated factor-1 as an interferon-stimulated gene that
augments TRAIL Apo2L-induced apoptosis.  J Biol Chem 2002,
277:28504-28511.
8. Xia Y, Novak R, Lewis J, Duckett CS, Phillips AC: Xaf1 can cooper-
ate with TNFalpha in the induction of apoptosis, independ-
ently of interaction with XIAP.  Mol Cell Biochem 2006,
286:67-76.
9. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk
RG: Expression and genetic analysis of XIAP-associated fac-
tor 1 (XAF1) in cancer cell lines.  Genomics 2000, 70:113-122.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:52 http://www.biomedcentral.com/1471-2407/7/52
Page 12 of 12
(page number not for citation purposes)
10. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG: Hyper-
methylation of XIAP-associated factor 1, a putative tumor
suppressor gene from the 17p13.2 locus, in human gastric
adenocarcinomas.  Cancer Res 2003, 63:7068-7075.
11. Karpf AR, Jones DA: Reactivating the expression of methyla-
tion silenced genes in human cancer.  Oncogene 2002,
21:5496-5503.
12. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA: Epi-
genetic silencing of multiple interferon pathway genes after
cellular immortalization.  Oncogene 2003, 22:4118-4127.
13. Chen B, He L, Savell VH, Jenkins JJ, Parham DM: Inhibition of the
interferon-gamma/signal transducers and activators of tran-
scription (STAT) pathway by hypermethylation at a STAT-
binding site in the p21WAF1 promoter region.  Cancer Res
2000, 60:3290-3298.
14. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D,
Ludwig C, Zangemeister-Wittke U, Stahel R: Silencing of death
receptor and caspase-8 expression in small cell lung carci-
noma cell lines and tumors by DNA methylation.  Cell Death
Differ 2003, 10:356-364.
15. Kim S, Kang J, Evers BM, Chung DH: Interferon-gamma induces
caspase-8 in neuroblastomas without affecting methylation
of caspase-8 promoter.  J Pediatr Surg 2004, 39:509-515.
16. Casciano I, Banelli B, Croce M, De Ambrosis A, di Vinci A, Gelvi I, Pag-
nan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M: Cas-
pase-8 gene expression in neuroblastoma.  Ann N Y Acad Sci
2004, 1028:157-167.
17. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS: Short
hairpin RNAs (shRNAs) induce sequence-specific silencing in
mammalian cells.  Genes Dev 2002, 16:948-958.
18. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandi-
malla ER, Agrawal S, Morris SJ, Durkin JP, Lacasse EC: Loss of XIAP
protein expression by RNAi and antisense approaches sensi-
tizes cancer cells to functionally diverse chemotherapeutics.
Oncogene 2004, 23:8105-8117.
19. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative
PCR.  Genome Res 1996, 6:986-994.
20. Herman JG, Baylin SB: Gene silencing in cancer in association
with promoter hypermethylation.  N Engl J Med 2003,
349:2042-2054.
21. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N,
MacLeod AR, Borden EC: Overcoming resistance to interferon-
induced apoptosis of renal carcinoma and melanoma cells by
DNA demethylation.  J Clin Oncol 2006, 24:3771-3779.
22. Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J,
He H, Jiang SH, Sun YW, Yu LF, Yuen ST, Kung HF, Wong BC: Cor-
relation between the single-site CpG methylation and
expression silencing of the XAF1 gene in human gastric and
colon cancers.  Gastroenterology 2006, 131:1835-1843.
2 3 . B e k i s z  J ,  S c h m e i s s e r  H ,  H e r n a n d e z  J ,  G o l d m a n  N D ,  Z o o n  K C :
Human interferons alpha, beta and omega.  Growth Factors
2004, 22:243-251.
24. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of
transcription factors as regulators of host defense.  Annu Rev
Immunol 2001, 19:623-655.
25. Baccala R, Kono DH, Theofilopoulos AN: Interferons as patho-
genic effectors in autoimmunity.  Immunol Rev 2005, 204:9-26.
26. Zhang XN, Liu JX, Hu YW, Chen H, Yuan ZH: Hyper-activated
IRF-1 and STAT1 contribute to enhanced Interferon stimu-
lated gene (ISG) expression by Interferon alpha and gamma
co-treatment in human hepatoma cells.  Biochim Biophys Acta
2006, 1759:417-425.
27. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H,
Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B:
DNMT1 and DNMT3b cooperate to silence genes in human
cancer cells.  Nature 2002, 416:552-556.
28. Wang J, He H, Yu L, Xia HH, Lin MC, Gu Q, Li M, Zou B, An X, Jiang
B, Kung HF, Wong BC: HSF1 down-regulates XAF1 through
transcriptional regulation.  J Biol Chem 2006, 281:2451-2459.
29. Wang J, Peng Y, Sun YW, He H, Zhu S, An X, Li M, Lin MC, Zou B,
Xia HH, Jiang B, Chan AO, Yuen MF, Kung HF, Wong BC: All-trans
retinoic acid induces XAF1 expression through an interferon
regulatory factor-1 element in colon cancer.  Gastroenterology
2006, 130:747-758.
30. Grander D, Einhorn S: Interferon and malignant disease--how
does it work and why doesn't it always?  Acta Oncol 1998,
37:331-338.
31. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA,
Abbruzzese A: Alpha-interferon and its effects on signal trans-
duction pathways.  J Cell Physiol 2005, 202:323-335.
32. Yoshida J, Mizuno M, Wakabayashi T: Interferon-beta gene ther-
apy for cancer: basic research to clinical application.  Cancer
Sci 2004, 95:858-865.
33. Van Geelen CM, de Vries EG, de Jong S: Lessons from TRAIL-
resistance mechanisms in colorectal cancer cells: paving the
road to patient-tailored therapy.  Drug Resist Updat 2004,
7:345-358.
34. Ruiz de Almodovar C, Lopez-Rivas A, Ruiz-Ruiz C: Interferon-
gamma and TRAIL in human breast tumor cells.  Vitam Horm
2004, 67:291-318.
35. Yang X, Thiele CJ: Targeting the tumor necrosis factor-related
apoptosis-inducing ligand path in neuroblastoma.  Cancer Lett
2003, 197:137-143.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/52/prepub